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INTRODUCTION
Primary prevention in public health and in the field 
of rare diseases
Since Hyppocrates, public health care means that, be-
sides treating disease when it occurs, science and actions 
should reduce the occurrence of diseases. This is specifi-
cally called “prevention”. Primary prevention includes the 
actions aimed at avoiding the onset of the disease. This 
means intervening before health effects occur, through 
measures modifying risk factors, their distribution or the 
way they reach the individual, for instance by banning 
substances or conditions known to be associated with 
one or more disease or adverse health status. Primary 
prevention, thus, results on eradicating, eliminating or 
minimizing the impact of disease and disability on the 
population, through interventions that are applied before 
there is any evidence of disease or injury, by controlling 
causative risk factors; the main focus are disease risk fac-
tors, in order to reduce the disease incidence.
Reducing disease incidence means a healthier soci-
ety, while reduced disease burden means improved life 
quality and working capacity, reduction of avoidable 
disabilities and mortality, and lower costs for diagnosis 
and treatments, among other advantages, for the indi-
vidual as well as for the society. Thus, strengthening and 
implementing primary prevention with the support of 
scientific evidence makes the healthcare system more 
efficient and sustainable, while providing significant 
benefits to society as a whole, apart from the individual 
tangible and intagible advantages.
The different and relevant disciplines and actors in-
volved in primary prevention often tend to think and 
operate in silos [1], concentrating on specific determi-
nants such as lifestyles or living environment. Indeed, 
the actual problems call for an integration and cross-fer-
tilization among different expertise fields. For instance, 
communities with low socio-economic status are more 
prone to live in more polluted settings, with insufficient 
availability of green areas or healthy food purchases. 
Therefore, it is also important to gather accurate data 
that can be analysed wisely to avoid confounding and 
to properly assess possible interactions of different vari-









Protection of early development contributes to health of next generations. Congenital 
anomalies (and other adverse reproductive outcomes) are an important public health is-
sue and early indicator of public health risks, as early development is influenced by many 
risk factors (e.g., nutrition, lifestyles, pollution, infections, medications, etc). Effective 
primary prevention requires an integrated “One Health” approach, linking knowledge 
and action. This requires surveillance of health events and potential health-damaging fac-
tors, science-based risk analysis, citizens’ empowerment and education of health profes-
sionals. From the policy standpoint, joint budgeting mechanisms are needed to sustain 
with equity intersectoral actions (involving policy domains of health, social affairs, edu-
cation, agriculture and environment). States should devote resources to strengthen reg-
istries and systematic data collection for surveillance of congenital anomalies, to better 
inform national prevention strategies. Investing in primary prevention based on scientific 
evidence is essential to support sustainable and resilient health systems and sustainable 
development of the society. 


















ables and linked factors. These accurate analyses will 
have an impact on the identification of risk factors and 
the delineation of primary prevention measures.
It is important to note that, although primary preven-
tion makes the health systems more sustainable, and 
despite its recognized major role among public health 
actions, paradoxically it does not attract a correspond-
ing fraction of resources devoted to health by policy 
makers. For instance, countries from the European 
Union (EU) overall allocate less than 3% of healthcare 
expenditure, and as low as 1% in some countries, to pri-
mary prevention actions [2].
The reduction of risk factors for poor health out-
comes may involve actions beyond the specific domain 
of healthcare systems. The capacity to fulfill the primary 
requirements (food security, housings), the quality and 
safety of living environment (air, water, food), the social 
environment (education, income, lifestyles), the deci-
sions of policy makers (in what refers to resources de-
voted to health services), are all determinants involved 
in increasing or reducing threats for health. In prin-
ciple, policies should consider their potential impact 
on health and undergo “health-proofing”, as recently 
implemented in Ireland and a few other EU Countries.
The 2013 Annual Growth Survey [3] recognised that 
“in the context of the demographic challenges and the 
pressure on age-related expenditure, reforms of health-
care systems should be undertaken to ensure cost-effec-
tiveness and sustainability, assessing the performance of 
these systems against the twin aim of a more efficient 
use of public resources and access to high quality health-
care”. The assessment of healthcare policies should be 
more prevention-oriented. Effective prevention is evalu-
ated on the basis of “diseases avoided”. This means that 
fit-to-purpose sets of performance indicators and out-
come measurements should be developed accordingly 
to better plan future programs and strategies.
When extending the considerations on primary pre-
vention to rare diseases, congenital anomalies (CA) rep-
resent a proper field of reflection and action. Many rare 
diseases are congenital because they result from altera-
tion of prenatal development. This means that their man-
ifestations are present at birth or can be even evident 
before the delivery. In fact, prenatal diagnosis is possible 
for many of them. CA, also known as birth defects, are 
defined by the World Health Organization (www.who.
int/topics/congenital_anomalies/en/) as structural or 
functional anomalies that occur during intrauterine life 
and can be identified prenatally, at birth or later in life. 
Indeed, CA represent an important fraction of rare dis-
eases and, at the same time, most CA can be considered 
rare diseases, based on their frequency [4]. They repre-
sent a significant health burden, leading to an overall in-
creased morbidity and to a considerable risk for prema-
ture death among affected people, as well as for lifelong 
disabilities and dependence in many surviving cases [4]. 
CA’s presence since birth or earlier implies that they, and 
their consequences, must be faced from that early point 
in life, Due to the critical role of non-genetic factors in 
their etiology, CA are the main group of rare diseases in 
which primary prevention measures have a known benefi-
cial impact. Indeed, since 2013 the European Union has 
endorsed a body of evidence-based Recommendations for 
primary prevention of CA [5]. These recommendations 
may be relevant to other adverse pregnancy outcomes as 
well (prematurity, stillbirths, developmental delays and 
related disabilities), and even they can have an impact 
on parents’ health (since for instance modifying lifestyles 
or adopting better protection in the workplace will also 
benefit them), as non-genetic risk factors are frequently 
shared. The Recommendations [5] discussed the differ-
ent institutional and societal levels relevant for develop-
ing and implementing primary prevention strategies.
MATERIALS AND METHODS
The paper reviews the main literature available on the 
primary prevention of rare diseases, with a special fo-
cus on CA. Several medical databases and additional 
information resources were utilised and included gov-
ernment documents, reports from international bodies 
such as the World Health Organisation, and academic 
studies. The key search terms were primary preven-
tion, congenital anomalies and rare diseases, from 
2000 through January 2018. Articles of interest were 
reviewed to determine which were relevant and sub-
jected to analysis. Selected papers were later used to 
extrapolate the most relevant messages about primary 
prevention of on CA.
RESULTS
The reviwe showed that the importance of CA on 
public health is clear: Christianson et al. [6] estimated 
that overall 7.9 million children are born each year with 
serious CA of genetic or partially genetic (multifacto-
rial, gene-environment) origin, and additional hundred 
thousand more are born with serious CA of post-con-
ception origin. In general, and depending on the popu-
lation considered, it is estimated that approximately 
3-6% of newborn infants worldwide are affected by seri-
ous CA [7-9]. Moreover, according to the 2015 Global 
Burden of Disease study, CA led to 8.5% (7.7-9.5%) 
of deaths under the age of 5 years in 2015 [10], and at 
least 3.3 million children under 5 years of age die from 
CA each year [9]. CA represented the most important 
cause of death below 5 years of age in countries with low 
and very low under-5 mortality [11]; in addition, Oza 
et al [12] observed that the proportion of deaths from 
CAs was relatively stable across their study period (data 
for 2000-2013 in 194 countries), showing the smallest 
relative decrease in risk compared to other causes (e.g., 
infections); some authors have estimated that mortality 
due to CA for the under-5 age group is likely to be a 
four-fold underestimate [13]. Beyond mortality, an esti-
mated 3.2 million of those who survive may be disabled 
for life [9]; disability-adjusted life-years (DALY) rates 
due to CA have increased lately [14]; the years lived 
with disability (YLD) have increased for CA [15]. Ter-
minations of pregnancy for CA were almost three times 
more frequent than infant deaths and stillbirths with 
CA combined [16], and this affects the Global Burden 
of Disease figures and their interpretation.
These eloquent figures, matched with their intrauter-
ine origin and the major role of non-genetic factors, en-
hance the interest of their study within the field of rare 


















diseases, and make them priority targets for research 
[17] and prevention. Primary prevention of CA is fea-
sible because scientific evidence points to several risk 
factors (e.g., obesity, infectious and toxic agents) and 
protective factors (e.g., folic acid supplementation and 
glycemic control in diabetic women) [18].
The bullet points below summarize the main fields 
pertinent to primary prevention of CA, encompassing 
both health systems and policies in relevant fields: 
• Actions to mitigate low socio-economic status and poor 
education might have an impressive impact on a num-
ber of critical determinants, such as lifestyles (tobac-
co smoking and alcohol drinking during pregnancy, 
among others), and unbalanced diet associated with 
the increased risk of overweight/obesity, which, in its 
turn, is a significant risk factor for CA. 
• Lifestyles can partly be tackled by specific policies, 
whose effectiveness should be evaluated in the con-
text of specific countries. It is critical to reduce the 
consumption of energy-dense foods and drinks, to-
bacco and alcohol: a combination of policy actions 
and individual empowerment, starting from school, 
seems a suitable general approach. For instance, in 
Italy, smoking in public places, including the work-
place, has been forbidden by law in 2003: the law, 
matched with publicly-supported anti-smoking adver-
tising, has been received by society with a favourable 
attitude and has contributed to reduce the number of 
smokers and especially the environmental exposure 
to passive smoking. Indeed, as already pointed out, 
exposure to tobacco smoking is a risk factor for CA 
and other adverse pregnancy outcomes.
• Low socio-economic status and poor education are 
associated with a reduced access to correct informa-
tion about health-protecting and health-promoting 
behaviours, such as the periconceptional supplemen-
tation with folic acid, and other preconception care 
measures. 
• The schooling system can play a major role in reducing 
health inequalities due to different socio-economic 
status and promoting health awareness and empow-
erment. The promotion of health literacy programmes 
since primary school can support the adoption of a 
healthy lifestyle from childhood; a timely empower-
ment during school age toward correct lifestyles and 
behaviors may significantly reduce the risk factors for 
CA in the next generation. 
• Actions to control and reduce the exposure to pollut-
ants in living environment, workplace and foods: the cur-
rent EU regulations on hazardous chemicals (e.g., the 
REACH regulation [19]) put emphasis on the identi-
fication and management of developmental toxicants. 
The EU food safety is possibly the domain where pre-
vention and control of pollutants is most developed: 
however, emphasis needs to be put on the identifica-
tion of emerging risks [20]. In particular, food safety 
systems should exploit the available knowledge to im-
prove prevention of long-term risks along the whole 
food chain, such as those related to endocrine dis-
rupting substances [21]. Full implementation of the 
EU regulations, currently the world’s most advanced 
ones, calls for a balance between scientific evidence, 
a reasonable use of the precautionary principle and 
the necessary involvement of the industrial and agro-
food sectors. 
• Pollution is not evenly distributed throughout the EU 
population: a number of areas are highly exposed to 
releases from toxic industrial activities and/or chemi-
cal waste from different sources (e.g., petrochemicals 
or persistent and bioaccumulative –“legacy” – con-
taminants). In communities with higher exposure to 
these hazardous chemicals in living environment, CA 
(together with other adverse reproductive outcomes) 
represent an important public health issue [22]. As 
shown, for instance, in Italy by Sentieri, a Istituto 
Superiore di Sanità-led project. CA are also a sensi-
tive sentinel for environmental quality [23], due to 
the relatively short latency time and the high suscep-
tibility of the intrauterine life to major toxicological 
modes of action, such as endocrine disruption.
• The majority of the EU population aged between 18 
and 65 years spends over half of their lives at the work-
place. Workplace represents a diversified environment 
where exposures through multiple physical, chemical 
and biological agents can occur: to date women at 
fertile age are involved in every job role in the EU. 
But importantly, also men can be exposed to these 
hazards in the workplace, therefore their gametes will 
form and mature in an environment that can have an 
impact on the risk for gene mutations as well as on 
fertility. Effective prevention and health monitoring 
interventions in the workplace should be achieved 
through the co-operative involvement of employers, 
workers, occupational health professionals and legis-
lators. Health and societal policies should recognize 
the basic right for a workplace environment that min-
imizes the health risks for workers as well as for their 
offspring.
• Chronic diseases such as diabetes, infectious diseases 
such as rubella and the emerging Zika viruses, as well 
as the inappropriate use of certain drugs, such as the 
antiepileptic drugs with known teratogenic efects, 
among others, are recognized risk facts for CA. Such 
risk factors can be significantly mitigated by function-
ing and accessible healthcare services. Hence, actions of 
top relevance for the protection of the generation(s) 
to come include the care for maternal chronic diseases 
(e.g., diabetes, epilepsy), the deliverance of vaccina-
tion programmes (e.g., toward rubella) and the en-
forcement of pharmacovigilance programmes. These 
measures are supported by teratology information ser-
vices where the different actors involved in primary 
prevention (health care professionals and lay people) 
can solve their questions on the different risks and 
possible measures. Such policies could also receive 
a significant support by fostering the consistent in-
volvement of pharmacists and nurses.
• Pre-conception care is surely the most effective way to 
put in practice all the known measures for primary 
prevention of CA, adapting them to the specific char-
acteristics of each couple. Therefore, policies should 
put special focus on the establishment of services spe-
cifically devoted to this approach by which risk fac-
tors can be identified, the most appropriate measures 


















can be adopted accordingly, the most convenient in-
formation can be provided (adapted to the specific 
characteristics of each couple of parents to be) by 
health care workers or specialists, and some preven-
tive measures can be put in practice.
• Pregnancy planning is another pivotal issue, that 
should be promoted by all means.
• The inadequate access to health services may be a spe-
cial concern for low-status population groups and/or 
groups considered as “marginal” (immigrants, gypsies 
and other social-cultural groups, isolated communi-
ties).  The primary prevention of CA in such popula-
tion groups may require, therefore, specific attention 
and ad hoc actions.
• Health systems include data collection and surveil-
lance: CA and rare disease registries of adequate 
quality can provide a valuable support to prevention 
strategies, e.g., by allowing ad hoc studies in order to 
assess potential risk factors (maternal diseases, drug 
treatment, occupation, etc.)  or preventive actions, 
e.g., the diffusion of periconceptional folic acid sup-
plementation at the right timing and dosing. 
• Also, considering that the frequency of every single 
CA is rather low, data sharing and networking are very 
important for the research of any aspect related to 
CA, but specifically on preventive measures [24]. 
DISCUSSION
In 2015, countries under the umbrella of United Na-
tions adopted the 2030 Agenda for Sustainable De-
velopment and its 17 Sustainable Development Goals 
[25]. Governments, businesses and civil society togeth-
er with the United Nations are mobilizing efforts to 
achieve the Sustainable Development Agenda by 2030. 
Universal, inclusive and indivisible, the Agenda calls for 
action by all countries to improve the lives of people 
everywhere. In particular Goal 3 “Ensure healthy lives 
and promote well-being for all at all ages” specifically 
states “Ensuring healthy lives and promoting the well-
being for all at all ages is essential to sustainable de-
velopment. Major progress has been made. However, 
many more efforts are needed to fully eradicate a wide 
range of diseases and address many different persistent 
and emerging health issues.”
Primary prevention, therefore, clearly pertains to the 
domain of sustainability. Health system sustainabil-
ity means that today’s efforts to protect and promote 
health will not reduce resources so to jeopardize the 
future efforts to provide an equitable and functioning 
health system to the next generation(s). Hence, owing 
to primary prevention, the health system will be more 
sustainable for the society. A science-based primary pre-
vention will reduce both burdens of premature deaths 
and of chronic disabilities (measureble as DALY) re-
lated to CA. This is important also in an ageing society: 
following the paradygm of “Developmental Origins of 
Health and Diseases”, an effective primary prevention 
in the early lifestages (starting from intrauterine life, 
and even preconceptionally) can improve the quality 
of life of the increasing aged population, and reduce 
the societal costs for long-term treatment and care of 
chronic, often invalidating conditions [26]. 
Data suggest that local and national public health in-
terventions are highly cost-saving. Cuts to public health 
budgets in high income countries therefore represent a 
false economy, and are likely to generate billions of eu-
ros of additional costs to health services and the wider 
economy [27].
Sustainable  development in the field of health is 
the goal of meeting the needs of the present without 
compromising the ability of future generations to cover 
their own needs. In the fields of food safety and envi-
ronmental health, for instance, the phasing-out and re-
placement of hazardous chemicals (such as mutagens, 
teratogens, endocrine disruptors) are actions that can 
reduce the burden of disease for generations to come, 
by enforcing a safer living environment today. Disease 
prevention must start with improved nutrition and re-
duced exposure to environmental chemicals during de-
velopment [26]. Also, sustainable food safety implies 
the efforts towards the comprehensive knowledge and 
management of key factors related to to food and diet 
for protecting and promoting next generation’s health; 
such efforts will contribute  to the effectiveness of the 
overall sustainability policies [28].
Besides sustainability, prevention may also involve 
the concept of resilience at different levels. 
Resilience means to adapt the system to changes in 
order to keep it functioning. The system must be able 
to adapt itself effectively to changing environments and 
identify and apply innovative solutions to tackle signifi-
cant challenges – shortages of expertise/resources in spe-
cific areas, unexpected surges in demand with limited 
resources. In other words, the system needs to build and 
maintain resilience. Emerging risks, presenting either as 
new hazards or as new aspects of recognized hazards, 
call for resilient responses: one example in CA field is the 
recently recognized teratogen Zika virus [29]. Emerging 
risks make evident the need for the health system to be 
able to understand changes and to adapt/modify its re-
sponses accordingly. The World Health Organization has 
considered Zika virus as a case study for emerging risk 
challenge. European countries can learn from the expe-
rience of other regions on how to communicate about 
Zika and apply these lessons to the European context, 
as the possible scenarios of Zika outbreaks can show sig-
nificant differences in terms of size, and composition of 
the population at risk, cultural and socioeconomic real-
ity and preparedness and response capacity.
To this respect, health promotion is important. It is the 
process of empowering people to increase control over 
their health and its determinants through health literacy 
efforts and multi-sectorial action to increase healthy be-
haviors. This can be addressed to the community-at-large 
or to populations at increased risk of negative health 
outcomes. Disease prevention and health promotion share 
many goals, and there is considerable overlap between 
functions. In fact, it is useful to characterize disease pre-
vention services as those primarily concentrated within 
the health system domain, while health promotion ser-
vices depend on intersectorial actions and/or are con-
cerned with the social determinants of health.
Primary prevention actions should be targeted based 
on scientific evidence. This statement should not hide 


















the many uncertainties still existing. A few examples 
of gaps of knowledge that increase the burden of un-
certainties on primary prevention actions regarding CA 
can be mentioned: in the field of health interventions, the 
benefit-to-risk assessment of flour fortification with fo-
lic acid; in the field of chemical safety, the possible role 
of developmental exposures to pollutants in the obesity/
diabetes epidemics; in the field of response to emerging 
risks, the role of climate changes on emerging infectious 
agents (such as Zika virus) and the associated terato-
genic risks; in the field of safe use of medications, the as-
sessment of possible risks derived from the use of herbal 
drugs and other widespread “alternative” medicines, in 
relation to pregnancy; in the field of safe food, undertak-
ing actions to identify and characterise emerging risks .
On one hand, the recognized presence of significant 
gaps of knowledge cannot, by any means, hamper the 
enforcement of evidence-based actions here and now.
On the other hand, and importantly, prevention needs 
research and innovation. An uncertainty is a gap of 
knowledge that can impair the assessment of the ben-
efits introduced by a certain action. Therefore, uncer-
tainties have to be identified and characterized, in order 
to plan and launch relevant research activities. Recently, 
it has been stated that for better sustainability and use-
fulness, it is crucial to refocus and streamline surveil-
lance activities, avoiding a “recreational” data collection, 
in order to turn the statistically significant results into 
clinically relevant data. Also, it has been recommended 
to perform a “triple surveillance” [30]: surveillance of 
causes, of disease occurrence, and of health outcomes. 
Such integral surveillance can be a really effective tool 
for primary prevention of CA.
RECOMMENDATIONS AND CONCLUSIONS
CA, which include an important fraction of rare 
diseases, are liable to risk reduction by means of sci-
ence-based primary prevention. In order to achieve an 
effective primary prevention, the following general rec-
ommendations have to be taken into account: 
• the professional education and training of all health 
professionals (not limited to physicians) should pro-
vide an adequate room to primary prevention from 
both the qualitative and quantitative standpoint; this 
should include epidemiology, social medicine, envi-
ronmental health, food safety and nutrition, as these 
themes can be relevant to the work of the majority of 
health professionals.
• EU Member States should consider the “health-
proofing” of all their policies. As pointed out in the 
above paragraphs, side to the health system, primary 
prevention involves several other legislative, interven-
tion and scientific domains.
• Health is a fundamental human right; at the same 
time, it can be considered that the “investment” on 
primary prevention generates both tangible and in-
tangible benefits. It has been said that “early child-
hood development is a smart investment” and “the 
earlier the investment the greater the return” [31]: 
investing in primary prevention is obviously the earli-
est possible investment. Nobel Laureate Economist 
James Heckman’s research makes the economic case 
for early childhood investments starting before birth.
In conclusion, the considerations on CA as an ex-
ample for primary prevention in the rare diseases field 
identify the following highlights:
1. investing in primary prevention based on scientific 
evidence is one essential factor supporting sustainabil-
ity of health systems;
2. primary prevention is a pillar of sustainable develop-
ment of the society; protection of the early develop-
ment will enable healthier next generation(s) reaching 
full adulthood and ageing;
3. in regard of many risk factors (e.g. nutrition, life-
styles, pollution, infections, medications), CA (together 
with other adverse reproductive outcomes) represent 
both an important public health issue per se as well as 
an early indicator of public health risks;
4. effective primary prevention requires an integrated 
“One Health” approach, linking knowledge and action 
pertaining to human health as well as to physical and 
social living environments. From the policy standpoint, 
joint budgeting mechanisms can be envisaged to sus-
tain intersectorial actions, involving the policy domains 
of health as well as others, e.g., social affairs, education, 
agriculture, and/or environment; 
5. EU Member States (and any country, in fact): should 
devote resources to strengthen registries, and other tools 
for systematic data collection and surveillance on CA, so 
as to better inform national prevention strategies.
6. pillars of primary prevention include science-based 
risk analysis and surveillance of potential health-dam-
aging factors, citizen’s empowerment and education of 
health professionals; 
7. characterization of uncertainties that weaken scien-
tific evidence should target research programmes aimed 
at supporting the scientific basis of primary prevention;
8. EU Member States should consider the health and 
equity aspects [32, 33] in all their policies (short, mid 
and long term). Moreover, The DG SANTE Scientific 
Committees recommend more dialogue between risk 
assessors and socio-economists [34].
In summary, primary prevention for CA as well as for 
other rare diseases, must be considered (better earlier 
than later) as a pillar of sustainability of health systems 
and a duty of policy makers with respect to society, 
which expects that the system provides a better quality 
of life to all, leaving no one behind.
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